Amgen, a manufacturer of human therapeutics, has appointed Jonathan Peacock as chief financial officer (CFO), effective 1 September 2010. He will be responsible for Amgen’s finance and investor relations operations. Peacock will report to Kevin Sharer, Amgen’s chairman and chief executive officer (CEO), and will succeed Michael Kelly, who served as acting CFO since May 2010.
Peacock joins from Novartis Pharmaceutical, where he served as CFO and administration officer since 2005. In that role, Peacock led the finance, information technology, purchasing, strategic planning and mergers and acquisitions functions.
Previously, Peacock was a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice working in the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St Andrews in Scotland and is a chartered accountant (CA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.